1 Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Öllinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Puhr R, Chkhartishvilli N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group.
J Acquir Immune Defic Syndr. 2020;83(3):240-250. Abstract

2 Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, Antinori A, Lampe F C, Youle M, Vehreschild J J, Mussini C, Borghi V, Begovac J, Duvivier C, Gunthard H F, Rauch A, Tiraboschi J, Chkhartishvili N, Bolokadze N, Wit F, Wasmuth J C, De Wit S, Necsoi C, Pradier C, Svedhem V, Stephan C, Petoumenos K, Garges H, Rogatto F, Peters L, Ryom L; RESPOND study group.
HIV Med. 2020. Abstract

3 How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. B Neesgaard *, A Mocroft, L Greenberg, JF Larsen, G Wandeler, R Zangerle, H Günthard, C Smith, S De Wit, C Mussini, A Castagna, a D'Arminio Monforte, JJ Vehreschild, JC Wasmuth, C Pradier, N Chkhartishvili, F W.N.M. Wit, M Law, A Sönnerborg, A Bruguera, C Stephan, V Vannappagari, R Haubrich, O Kirk, D Podlekareva, J Kowalska, D Raben, J Rockstroh, L Peters, R Parades, K Grabmeier-Pfistershammer, A Scherrer, M Johnson, C Necsoi, V Borghi, C Muccini, T Tserstvadze, K Petoumenos, A Volny-Anne, J Lundgren, L Ryom, for the RESPOND study group
Microorganisms. 2020;8(8):E1164. Abstract

4 The interrelationship of smoking, CD4+ cell count, viral load and cancer in persons living with HIV. Mocroft A, Petoumenos K, Wit F, Vehreschild JJ, Guaraldi G, Miro JM, Greenberg L, Oellinger A, Egle A, Günthard HF, Bucher HC, De Wit S, Necsoi C, Castagna A, Spagnuolo V, D’Arminio Monforte A, Reiss P, Chkhartishvili N, Bolokadze N, Hoy J, Sonnenborg A, Svedhem V, Bower M, Volny-Anne A, Garges H, Rogatto F, Neesgaard B, Peters L, Lundgren JD, Ryom L, RESPOND study group
AIDS. 2020;35(5):747-757.  Abstract

5 Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, Wit F, Lehmann C, d'Arminio Monforte A, Miró JM, Castagna A, Spagnuolo V, Sönnerborg A, Law M, Hutchinson J, Chkhartishvili N, Bolokadze N, Wasmuth JC, Stephan C, Vannappagari V, Rogatto F, Llibre JM, Duvivier C, Hoy J, Bloch M, Bucher HC, Calmy A, Volny Anne A, Pelchen-Matthews A, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND study group.
Clin Infect Dis. 2020. Abstract

6 Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.  
Bastian Neesgaard, Amanda Mocroft, Robert Zangerle, Ferdinand Wit, Fiona Lampe, Huldrych F Günthard, Coca Necsoi, Matthew Law, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Christian Pradier, Nikoloz Chkhartisvilli, Juliana Reyes-Uruena, Jörg Janne Vehreschild, Jan-Christian Wasmuth, Anders Sönnerborg, Christoph Stephan, Lauren Greenberg, Josep M Llibre, Alain Volny-Anne, Lars Peters, Annegret Pelchen-Matthews, Vani Vannappagari, Joel Gallant, Armin Rieger, Mike Youle, Dominique Braun, Stephane De Wit, Kathy Petoumenos, Vanni Borghi, Vincenzo Spagnuolo, Tengiz Tsertsvadze, Jens Lundgren, Lene Ryom, RESPOND study group 
PLoS One . 2020;15(12):e0243625.  Abstract








  Custom Editor Options SaveCancelEditPreviewVersion History Rich Text Editor